Our studies have indicated that LY2784544 can efficiently re-sensitize cisplatin-resistant NPC cells to cisplatin via inhibition of JAK2, which eventually blocks IL6 autocrine activity. The gene discussed is IL6; the disease is nasopharyngeal carcinoma.